ArticleBeyoglu eye journal2025
The Role of Botulinum Toxin in Dry Eye Disease and Meibomian Gland Dysfunction Associated with Hemifacial Spasm.
Article in Beyoglu eye journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To investigate the signs and symptoms of dry eye disease (DED) in patients with hemifacial spasm (HFS) through the evaluation of ocular surface measurements and meibomian gland function, and to assess the effects of botulinum toxin type A (BTX-A) injection on ocular surface health. Methods: This prospective study included patients with unilateral HFS who underwent BTX-A injection as treatment. Eyes on the same side as the spasm were defined as the HFS group, whereas the contralateral, unaffected eyes were used as controls. Ocular surface assessments included the ocular surface disease ındex (OSDI) score, Schirmer's I test, tear break-up time (TBUT), corneal surface staining, eyelid margin abnormalities, and meibomian gland function. All evaluations were repeated at 1, 3, and 6 months following BTX-A injection. Results: Compared to the control group, the HFS group demonstrated significantly higher OSDI scores, corneal surface staining, eyelid margin abnormalities, meibomian gland expression scores, meibography scores, and meibomian gland loss, whereas TBUT and Schirmer's I test values were significantly lower (p<0.05). A significant correlation was observed between the severity of HFS and ocular surface dysfunction, including meibomian gland dysfunction (MGD) (p<0.05). Following BTX-A injection, ocular surface parameters showed significant improvement at 1 month (p<0.05) and 3 months (p<0.05) compared to pre-injection values. Conclusion: We found an association between HFS and DED, which was correlated with the severity of HFS. In addition, BTX-A injection led to a temporary improvement in dry eye signs and symptoms, including MGD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.